VISUfarma SpA

VISUfarma SpA is an Italian pharmaceutical company headquartered in Rome and dedicated to the ophthalmology sector. According to the company's own account, it was founded in Rome in 1996 and operates as a single-shareholder company (Società con Socio Unico). Its business is built around the development, scientific information and commercialisation of eye-care medicines and related products aimed at ophthalmologists and their patients. The company describes itself as a pharmaceutical firm specialised in ophthalmology, with staff training and continuous scientific updating presented as core strengths. This emphasis reflects the nature of the ophthalmic market, where products are typically prescribed or recommended by specialists and where accurate, up-to-date information on correct use is essential. VISUfarma states that it maintains a national network of scientific information representatives (ISF) covering the whole of Italy, through which it interacts directly with eye specialists. Research and development is a central part of the company's positioning. VISUfarma reports having obtained a patent valid across all European Union countries for coenzyme Q10 delivered via vitamin E-TPGS, a formulation that makes the substance water-soluble and therefore suitable for administration as eye drops. This kind of formulation work — improving the solubility, stability or bioavailability of active ingredients for topical ocular use — is characteristic of the niche in which the company operates. The company frames its mission around improving the quality of its products and investing in ophthalmology research and development, seeking to combine product efficacy with the experience of specialists for the benefit of patients and their quality of life. Continuous interaction with specialists is described as a fundamental principle of its strategic approach. VISUfarma's market is primarily Italian, served through its own scientific information network and relationships with ophthalmology specialists. As a privately held, single-shareholder company, it does not publish the disclosure required of listed firms, and detailed financial information is not publicly available in the sources consulted. Its identity is that of a focused, specialist pharmaceutical player rather than a diversified multinational: a Rome-based ophthalmic pharmaceutical company whose brand is associated with eye-drop formulations, scientific detailing to specialists, and formulation research such as the coenzyme Q10 eye-drop patent.

VISUfarma SpA was founded in Rome in 1996, according to the company's own corporate profile. From its base in the Italian capital it developed as a pharmaceutical company focused specifically on ophthalmology, rather than as a generalist drug manufacturer. This specialisation shaped its commercial model: instead of mass-market consumer distribution, it built its activity around relationships with eye specialists and the scientific information that supports the correct use of ophthalmic products. A defining element of the company's development has been its investment in research and development within ophthalmology. VISUfarma reports that it obtained a patent valid in all European Union countries for coenzyme Q10 delivered by means of vitamin E-TPGS, a formulation that renders the substance water-soluble and thus suitable for administration as eye drops. This patent is presented by the company as a concrete outcome of its R&D commitment and as an example of the formulation science that distinguishes its product range. Alongside R&D, VISUfarma built a national scientific information capability. The company states that a network of scientific information representatives (ISF) operates across the whole of Italy, providing specialists with correct information on the use of its products. Staff training and continuous scientific updating are described as among the company's greatest strengths, reflecting the importance of accurate specialist-facing information in the ophthalmic field. The company operates as a single-shareholder company (Società con Socio Unico), a legal form common among privately held Italian businesses. It is headquartered in Rome and its primary market is Italy. Its stated mission is to invest in improving the quality of its products and in ophthalmology research and development, seeking to combine product efficacy with the experience of specialists for the benefit of patients and to contribute to improving patients' quality of life. Continuous interaction with specialists is described as a fundamental principle of its strategic approach. The sources consulted do not provide a detailed chronology of ownership changes, product launches by year, or financial results, so the company's history is best characterised as that of a stable, specialist, privately held ophthalmic pharmaceutical firm based in Rome, active in the Italian market since the mid-1990s.

• 1996

  VISUfarma SpA founded in Rome, Italy.

• Obtained a patent valid in all European Union countries for coenzyme Q10 delivered via vitamin E-TPGS, making it water-soluble for eye-drop administration.

Specialist Italian ophthalmic pharmaceutical company combining product efficacy with specialist experience, supported by a national scientific information network and formulation R&D.

• Ophthalmic pharmaceutical products

  Medicines and eye-care products for the ophthalmology sector.

• Coenzyme Q10 eye drops (vitamin E-TPGS formulation)

  A water-soluble coenzyme Q10 formulation patented for eye-drop administration across the EU.

1. 1Homepage - Visufarma S.p.a.visufarma.it
2. 2Chi siamo - Visufarma S.p.a.visufarma.it
3. 3VISUfarma SpA (Italy) - Wikidatawikidata.org